Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan W Friedberg

Blood

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Blood|May 21, 2011
Hodgkin lymphoma: answers take time!Jonathan W Friedberg
Blood|June 11, 2017
How I treat double-hit lymphomaJonathan W Friedberg
Blood|December 16, 2014
Transformed follicular non-Hodgkin lymphomaCarla Casulo, W Richard Burack, Jonathan W Friedberg
Blood|June 25, 2015
Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS)Nina D Wagner-Johnston, Brian K Link, Michelle Byrtek, et al.
Blood|September 11, 2004
Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicityJonathan W Friedberg, Helen Kim, Mary McCauley, et al.
Blood|November 10, 2023
Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapyJonathan W Friedberg, Rodolfo Bordoni, Dipti Patel-Donnelly, et al.
Blood|August 30, 2002
Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factorsAndrea K Ng, M V Patricia Bernardo, Edie Weller, et al.
Blood|February 7, 2009
Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximabShannon P Hilchey, Ollivier Hyrien, Tim R Mosmann, et al.
Blood|October 18, 2017
Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HLJonathan W Friedberg, Andres Forero-Torres, Rodolfo E Bordoni, et al.
Blood|March 11, 2015
The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemiaJennifer R Brown, Jacqueline C Barrientos, Paul M Barr, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Blood|May 21, 2011
Hodgkin lymphoma: answers take time!Jonathan W Friedberg
Blood|June 11, 2017
How I treat double-hit lymphomaJonathan W Friedberg
Blood|December 16, 2014
Transformed follicular non-Hodgkin lymphomaCarla Casulo, W Richard Burack, Jonathan W Friedberg
Blood|June 25, 2015
Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS)Nina D Wagner-Johnston, Brian K Link, Michelle Byrtek, et al.
Blood|September 11, 2004
Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicityJonathan W Friedberg, Helen Kim, Mary McCauley, et al.
Blood|November 10, 2023
Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapyJonathan W Friedberg, Rodolfo Bordoni, Dipti Patel-Donnelly, et al.
Blood|August 30, 2002
Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factorsAndrea K Ng, M V Patricia Bernardo, Edie Weller, et al.
Blood|February 7, 2009
Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximabShannon P Hilchey, Ollivier Hyrien, Tim R Mosmann, et al.
Blood|October 18, 2017
Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HLJonathan W Friedberg, Andres Forero-Torres, Rodolfo E Bordoni, et al.
Blood|March 11, 2015
The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemiaJennifer R Brown, Jacqueline C Barrientos, Paul M Barr, et al.
Pageof 4